Gufic Biosciences Q2 FY27 Results Due November 14, 2026

Gufic Biosciences Ltd. is scheduled to announce its Q2 FY27 results on November 14, 2026, with its latest stated comparable performance showing Q2 FY26 revenue of Rs 230 crore and EBITDA of Rs 37.9 crore. The disclosure will provide the first confirmed financial update for the September 2026 quarter in the supplied information.

When will Gufic Biosciences report Q2 FY27 results?

Gufic Biosciences is scheduled to report its Q2 FY27 results on November 14, 2026. The information provided does not include the company’s unaudited financial statement, revenue, profit, margin, balance-sheet figures or management commentary for the September 2026 quarter. Therefore, the scheduled reporting date is the confirmed event, rather than any reported Q2 FY27 financial outcome.

The company’s result announcement will be relevant because it is expected to provide updated standalone and consolidated performance information for the quarter. Investors will be able to compare the disclosed numbers with earlier reported quarterly metrics, including revenue, EBITDA, profit before tax and profit after tax. Until the results are released, no conclusion can be drawn from the supplied material on growth or profitability in Q2 FY27.

The disclosed result-day watch list also refers to earlier regulatory filings and board actions. These include past approvals of quarterly financial results under the Securities and Exchange Board of India listing regulations. Such disclosures establish the company’s reporting process but do not provide a financial forecast for Q2 FY27.

What was Gufic Biosciences' most recent reported quarterly performance?

Gufic Biosciences reported total revenue of Rs 230 crore for Q2 FY26, compared with Rs 227 crore in Q1 FY26, according to management’s November 17, 2025 earnings-call transcript. EBITDA rose to Rs 37.9 crore from Rs 33.2 crore over the same sequential comparison, while the EBITDA margin improved to 16.45% from 14.63%.

Profit before tax for Q2 FY26 was Rs 20.5 crore, against Rs 16.3 crore in Q1 FY26. The corresponding PBT margin increased to 8.9% from 7.18%. Profit after tax was Rs 14.9 crore, compared with Rs 12.1 crore in the preceding quarter, and the PAT margin improved to 6.47% from 5.32%.

A separate November 2024 transcript reported revenue of Rs 204.2 crore for Q2 of the then-current financial year, compared with Rs 214.9 crore in the comparable prior-year Q2. That disclosure also reported EBITDA of Rs 38.7 crore, profit before tax of Rs 29.3 crore and profit after tax of Rs 21.8 crore. These figures are historical reference points and should not be treated as Q2 FY27 estimates.

Which corporate actions have Gufic Biosciences disclosed recently?

Gufic Biosciences disclosed two senior management promotions effective September 2 and the re-appointment of Pankaj Jayakumar Gandhi as Whole-Time Director for five years effective September 2026. The provided information describes these as routine governance and management actions, with no strategic shift indicated.

The company had earlier informed exchanges that its board, at a meeting on August 13, 2025, approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The board also approved the re-appointment of Poddar & Co., Cost Accountants, as cost auditor for FY26.

In another disclosed governance matter, the board approved continuation of Dilip Ghosh as Whole-Time Director through his existing term ending November 11, 2025, subject to shareholder approval through a special resolution. Earlier board actions also covered the re-appointment of directors, including Jayesh Pannalal Choksi and Pranav Jayesh Choksi for terms beginning in April 2020.

These actions are separate from quarterly operating performance. Their immediate relevance for shareholders is governance continuity and compliance with listing-related disclosure requirements, rather than a confirmed change in revenue strategy, acquisitions or operating guidance.

What should investors examine in the Q2 FY27 announcement?

Investors should examine whether Gufic Biosciences reports changes in revenue, EBITDA and profit margins from the Q2 FY26 and Q1 FY26 benchmarks disclosed by management. Revenue of Rs 230 crore, EBITDA of Rs 37.9 crore and a 16.45% EBITDA margin are the latest quarterly figures in the supplied material that can serve as a factual comparison base.

The relationship between revenue and profitability will be important. In Q2 FY26, revenue increased by Rs 3 crore sequentially, while EBITDA increased by Rs 4.7 crore and profit after tax rose by Rs 2.8 crore. The resulting increases in EBITDA, PBT and PAT margins were reported by management, but the provided information gives no indication whether these trends continued into Q2 FY27.

Investors should also distinguish reported financial outcomes from board and personnel decisions. The September 2026 re-appointment of Pankaj Jayakumar Gandhi and the senior management promotions may be relevant to leadership continuity, but the material does not link them to a stated financial target or a planned transaction.

The Q2 FY27 release could also clarify any developments in business operations, cost structure or product demand if the company discloses them. No such updates are available in the supplied source before the scheduled result date, so any assessment should rely on the formal announcement and accompanying management communication.

Conclusion

Gufic Biosciences enters its Q2 FY27 result date with a historical reference point of Rs 230 crore in Q2 FY26 revenue, Rs 37.9 crore in EBITDA and Rs 14.9 crore in profit after tax. Management had reported sequential improvement in margins during that earlier quarter, while subsequent disclosures in the supplied information focused on routine governance, cost-auditor and leadership matters.

The next item to watch is the November 14, 2026 Q2 FY27 announcement, particularly the reported revenue, EBITDA, profit and margin figures against the Q2 FY26 and Q1 FY26 benchmarks. Investors can also watch for any formal operational commentary or targets disclosed alongside the results, as none are stated in the material provided before the result date.